Unexo Life Sciences Faces FDA Class II Recall for 6.8 Million ABSORBINE jr. Menthol Patches Over cGMP Deviations
Unexo Life Sciences Private Limited initiated a Class II recall of 6,848,820 ABSORBINE jr. Extra Large BACK PATCH, Menthol 5%, due to cGMP deviations. This event, now terminated, highlights critical quality control risks for procurement and supply chain leaders sourcing from India, demanding rigorous due diligence to mitigate disruption and ensure product integrity in the US market.
FDA Class II Recall: Unexo Life Sciences' cGMP Deviations Impact ABSORBINE jr. Supply
Unexo Life Sciences Private Limited, based in New Delhi, India, initiated a Class II voluntary recall (D-0062-2025) for 6,848,820 units of ABSORBINE jr. Extra Large BACK PATCH, Menthol 5%. This significant action, commencing on October 24, 2024, and officially terminated on September 16, 2025, was prompted by identified deviations from current Good Manufacturing Practices (cGMP). For procurement directors and supply chain VPs, this event underscores the critical importance of stringent quality oversight for contract manufacturing organizations (CMOs), particularly those operating in international jurisdictions. The volume of affected product, distributed nationwide in the US, indicates a substantial commercial impact, requiring immediate assessment of inventory levels and potential sourcing gaps. Regulatory affairs heads must note that cGMP deviations, even for over-the-counter products like this topical analgesic, are a serious concern for the FDA, potentially leading to further scrutiny of the manufacturer's entire quality system. This incident necessitates a review of existing supplier qualification processes and ongoing monitoring programs to prevent similar disruptions and maintain market access for essential health products.
Product and Company Profile: Unexo Life Sciences and the Recalled Menthol Patches
The recalled product, ABSORBINE jr. Extra Large BACK PATCH, Menthol 5%, is a topical analgesic distributed by Absorbine Jr., LLC of Chattanooga, TN 37402. The affected batches are identifiable by UPCs 8 89476 41218 6 and 8 89476 41236 0. Unexo Life Sciences Private Limited, the recalling firm, operates from B16, Sector 4, Bawana Industrial Area, New Delhi, India. This recall highlights the reliance of US-based distributors like Absorbine Jr., LLC on international manufacturing partners for consumer health products. For business development executives, this situation emphasizes the need for robust due diligence when forming partnerships with overseas CMOs, ensuring their quality systems align with FDA expectations from the outset. The sheer quantity of 6,848,820 patches involved represents a considerable manufacturing output from the New Delhi facility, making any quality lapse at this scale a major concern for continuity of supply. Companies sourcing similar topical formulations or other finished dosage forms from Unexo or other Indian manufacturers should evaluate their exposure to potential cGMP non-compliance, as the FDA's reach extends globally to ensure product safety and quality for the US market.
Supply Chain Exposure: Nationwide Distribution and Commercial Impact in the US
The distribution pattern for the ABSORBINE jr. Menthol 5% patches was "Nationwide in the US," indicating widespread market penetration and significant commercial exposure for Absorbine Jr., LLC and its retail partners. This broad distribution means that the cGMP deviations at Unexo Life Sciences directly impacted a vast network of pharmacies, big-box retailers, and online channels across the United States. For procurement directors, this event necessitates an immediate assessment of inventory levels for similar product lines and a review of contractual agreements with distributors regarding recall liabilities and replacement product sourcing. The recall of nearly 7 million units represents a substantial loss of sales volume and potential market share during the period of disruption. Supply chain VPs must consider the logistical complexities and costs associated with retrieving and disposing of such a large volume of product from a nationwide distribution network. This incident serves as a stark reminder that quality issues at the manufacturing origin can cascade rapidly through the entire supply chain, leading to significant financial and reputational damage for all parties involved in bringing the product to market.
Broader Regulatory Context: Persistent cGMP Challenges in Global Pharmaceutical Supply Chains
The cGMP deviations cited in Unexo Life Sciences' recall are not an isolated incident but reflect a broader pattern of quality control challenges within global pharmaceutical and life sciences supply chains. Recent parallel events underscore this systemic risk: Sandoz faced a Class II recall for Enoxaparin Sodium due to critical cGMP temperature excursion risks, while Teva Pharmaceuticals' Warfarin Sodium and Allergan's ARMOUR THYROID were impacted by Cardinal Healthcare's storage-related cGMP deviations. These examples, alongside Pfizer's Class I recalls for Bleomycin and Sodium Bicarbonate Injections due to glass particulate matter, highlight the diverse nature of cGMP non-compliance, ranging from manufacturing processes to storage and distribution. For regulatory affairs heads, these recurring issues emphasize the FDA's consistent focus on cGMP adherence across the entire product lifecycle. Companies relying on international CMOs, particularly from regions with high manufacturing volumes like India, must implement enhanced vendor qualification programs, conduct frequent unannounced audits, and establish robust quality agreements that mandate immediate reporting of any potential cGMP breaches. Failure to do so exposes businesses to not only product recalls but also potential import alerts, market withdrawal costs, and significant brand erosion.
Recall Resolution and Future Compliance Outlook for Unexo Life Sciences
The FDA's classification of the Unexo Life Sciences recall as "Terminated" on September 16, 2025, signifies that the firm has completed all necessary actions to remove the affected ABSORBINE jr. Menthol 5% patches from the market and has addressed the immediate cGMP deviations to the satisfaction of the agency. While the termination of the recall provides some closure, it does not erase the underlying compliance issues that led to the event. For business development executives and procurement teams, this means that while the immediate product threat is resolved, the regulatory scrutiny on Unexo Life Sciences' New Delhi facility is likely to persist. Future FDA inspections or audits could be triggered, and any recurrence of cGMP non-compliance could lead to more severe enforcement actions, including Warning Letters or Import Alerts, which would severely restrict market access to the US. Companies currently sourcing or considering sourcing from Unexo Life Sciences must demand comprehensive documentation of the root cause analysis for these cGMP deviations and evidence of effective corrective and preventive actions (CAPAs). This proactive approach is essential for mitigating future supply chain risks and ensuring continuous compliance with rigorous FDA quality standards.